Immunotherapies, including scFvs, are available for a diversity of neurological disorder targets such as semaphorin 4D (Huntington’s disease); nerve growth factor; tau; α-synuclein; and amyloid β (Alzheimer’s disease, ALS, Parkinson’s disease) [23,24]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.